price feb usd
updat growth driver
buy rate agil reect view compani opportun
growth margin expans capit deploy peer review
key growth opportun biopharma china chemic larg support
thesi albeit nuanc maintain buy rate increas
price target reect roll-forward valuat
methodolog one quarter
nucleic acid manufactur nich busi still nice growth
meaning new capac slate come line year agil nucleic
acid solut divis nasd background work better
understand market conclus might best describ mix sinc
view opportun increasingli nich limit nonetheless
market structur nucleic acid activ pharmaceut ingredi api
manufactur attract essenti player market agil
uniqu technolog see path support near-term sale ramp
compris agil sale growth per model
leverag chemic infrastructur spend china tari impact
china strength continu core tool group dec-q earn
season growth rate rang think especi
interest even industri market china sustain inde
agil chemic energi exposur cyclic develop market
believ secular growth compon exposur china
major coal-to-chem invest provid secular tailwind
expect invest moder slower growth econom
pressur motiv trade disput scan recent commun
agil custom suggest demand soft china con area like
consum esp softlin automot area directli relev agil
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
still growth
meaning new capac slate come line year agil nucleic
acid solut divis nasd background work better
understand market
conclus might best describ mix sinc view
opportun increasingli nich limit least near term
market nucleic acid drug incorpor oligo short dna
rna molecul api nascent count drug fda-approv
moreov meaning clinic activ appear driven hand
compani alnylam ioni partner medicin compani near-
slate fda catalyst presum submiss
cholesterol drug inclisiran gene edit strategi compris increment
opportun develop molecul earli day could
year away fda approv
nonetheless market structur nucleic acid api manufactur
attract agil technolog
essenti player market agil hold posit
figur nucleic acid api contract mfg market domin player
moreov agil appear uniqu technolog rna synthesi
includ patent chemic process elimin step rna
synthesi therebi reduc product time
number drug util nucleic acid api increas
see increas trend nucleic acid drug albeit small base
illustr follow gure
figur increas trend clinic trial nucleic acid drug
thu see path support near-term sale gure agil
agil nasd busi current compris compani
revenu compris sale growth forecast agil
figur inect nasd compris
coal-to-chem
stori china
china strength continu core tool group dec-q earn
season growth rate rang think especi
interest even industri market china sustain
agil chemic energi exposur cyclic develop
market believ secular growth compon
exposur china
china sit world largest coal reserv still deriv major
energi coal illustr follow gure
figur energi consumpt china still mostli coal
eort har coal suppli turn coal chemic provid
secular tailwind supplier analyt equip like ga chromatographi
product categori led agil recent high prole announc summar
follow gure suggest secular trend
figur exampl chemic infrastructur invest china
coaloilhydroelectr powernatur gasoth contract build largest coal chemic complex cooper framework build multi-billion chemic complex guangdong februari
expect type invest moder slower
growth econom pressur motiv trade disput inde capit
spend sinopec increas
moreov scan recent commun agil custom suggest
demand soft china con area like consum esp softlin
automot area directli relev agil
period end incom expens expens incom share share ep dilut per sale oper cash flowoper cash cash revenu
period end equival st current equip intang asset cash lt sharehold equityaccount matur lt current liabil sh equiti minor februari
